NEW YORK (GenomeWeb) – Illumina and Chinese clinical testing firm KingMed Diagnostics have partnered to develop next-generation sequencing-based oncology and hereditary disease diagnostics for the Chinese market.

Under the agreement, the companies will codevelop an NGS system based on Illumina's MiniSeq technology and KingMed's library prep kits and analysis.